Novan, Inc. News Releases http://investors.novan.com/ Novan, Inc. News Releases en Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology http://investors.novan.com/news-releases/news-release-details/novan-present-clinical-data-annual-meeting-society-investigative MORRISVILLE, N.C. , May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum Tue, 07 May 2019 16:15:00 -0400 Novan, Inc. News Releases 8021 Novan Completes Funding Transaction with Ligand Pharmaceuticals http://investors.novan.com/news-releases/news-release-details/novan-completes-funding-transaction-ligand-pharmaceuticals Novan to immediately receive $12 million of non-dilutive capital Ligand to receive milestones and tiered royalty for North America SB206 molluscum indication Phase 3 molluscum trial to begin recruitment of patients this month Molluscum top line results targeted early during the first quarter of Mon, 06 May 2019 09:00:00 -0400 Novan, Inc. News Releases 8016 Novan Confirms Corporate Update Conference Call and Webcast http://investors.novan.com/news-releases/news-release-details/novan-confirms-corporate-update-conference-call-and-webcast MORRISVILLE, N.C. , May 01, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clinical Wed, 01 May 2019 08:15:00 -0400 Novan, Inc. News Releases 7996 Novan Secures Up to $35 Million in Non-Dilutive Funding http://investors.novan.com/news-releases/news-release-details/novan-secures-35-million-non-dilutive-funding $25 million provided immediately in exchange for participation in future potential cash flows Additional $10 million available upon achieving success in molluscum Phase 3 top line results Pipeline Priority: initiation of Phase 3 molluscum program in May 2019 with top line readout targeted for first Mon, 29 Apr 2019 16:15:00 -0400 Novan, Inc. News Releases 7976 Novan and Sato Advance Japan Market and Dermatology Partnership http://investors.novan.com/news-releases/news-release-details/novan-and-sato-advance-japan-market-and-dermatology-partnership Dr. Elizabeth Messersmith named chairperson of the Sato and Novan Joint Committee Simultaneous clinical development progress for SB206 in Japan and US underway Novan receives second installment of $4.5 million under the SB206 Japan license agreement MORRISVILLE, N.C. Tue, 19 Mar 2019 09:01:30 -0400 Novan, Inc. News Releases 7891 Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates http://investors.novan.com/news-releases/news-release-details/novan-completes-end-phase-2-meeting-and-provides-additional Completed end-of-Phase 2 FDA meeting for molluscum contagiosum Meeting minutes received and support second quarter 2019 pivotal Phase 3 initiation Finalizing establishment of Irish entity to enable EU regulatory and partnering progress Shareholder class action lawsuit has been dismissed Letter of Mon, 11 Mar 2019 08:00:41 -0400 Novan, Inc. News Releases 7886 Novan Provides Business Update http://investors.novan.com/news-releases/news-release-details/novan-provides-business-update End-of-Phase 2 meeting with FDA for molluscum granted and scheduled for early March Active business development discussions ongoing around certain late-stage assets and broader dermatology platform Dr. David Hebert joins Novan as Senior Director of Biometrics John M. Wed, 30 Jan 2019 16:15:00 -0500 Novan, Inc. News Releases 7881 Novan Announces Management Changes and Provides Business Update http://investors.novan.com/news-releases/news-release-details/novan-announces-management-changes-and-provides-business-update Paula Brown Stafford promoted to President and newly created role of Chief Operating Officer of Novan Dr. Carri Geer promoted to Senior Vice President and Chief Technology Officer Dr. Elizabeth Messersmith , Senior Vice President, promoted to Chief Development Officer Novan adds gastroenterology as Wed, 02 Jan 2019 06:15:46 -0500 Novan, Inc. News Releases 7876 Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit http://investors.novan.com/news-releases/news-release-details/novan-present-data-sb414-phase-1b-atopic-dermatitis-clinical Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle   Strong anti-pruritic (itch) effect as measured by improvement on the pruritus (itch) numeric rating scale (NRS) compared to vehicle Clinical data Tue, 11 Dec 2018 08:01:02 -0500 Novan, Inc. News Releases 7871 Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily http://investors.novan.com/news-releases/news-release-details/novan-announces-full-top-line-results-phase-2-molluscum SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p Mon, 10 Dec 2018 07:30:22 -0500 Novan, Inc. News Releases 7866